Literature DB >> 6808027

Bence Jones proteins and light chains of immunoglobulins. Preferential association of the V lambda VI subgroup of human light chains with amyloidosis AL (lambda).

A Solomon, B Frangione, E C Franklin.   

Abstract

An antiserum prepared against a lambda-Bence Jones protein from a patient (SUT) who had multiple myeloma and amyloidosis had specificity for lambda-light chains of the chemically defined variable (V) region lambda-chain subgroup lambda VI. Sequence analyses of protein SUT and of five other lambda-light chains recognized immunologically as of the V lambda VI subgroup revealed that all six proteins had the N-terminal sequence characteristic for prototype lambda VI proteins. The isotypic nature of the V lambda VI subgroup was demonstrated immunochemically: lambda VI molecules were detected among light chains isolated from the IgG proteins of each of 12 normal individuals and lambda VI antigenic determinants were also detectable on the intact IgG proteins. The frequency of lambda VI molecules among lambda-type light chains is estimated to be approximately 5% based on the finding that 5 of 91 lambda Bence Jones proteins were of the V lambda VI subgroup. Proteins of the V lambda VI subgroup, in contrast to those of the other five chemically-classified lambda chain subgroup, appear to be preferentially associated with the amyloid process as evidenced by the fact that all six lambda VI proteins were obtained from patients with amyloidosis AL and, in addition, 5 of 42 lambda-type monoclonal immunoglobulins from patients with primary or myeloma-associated amyloidosis were classified by immunodiffusion analyses as having lambda VI-type light chains.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6808027      PMCID: PMC371254          DOI: 10.1172/jci110635

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  20 in total

Review 1.  Amyloidosis: its nature and pathogenesis.

Authors:  G G Glenner; W D Terry; C Isersky
Journal:  Semin Hematol       Date:  1973-01       Impact factor: 3.851

2.  Bence-Jones proteins and light chains of immunoglobulins. VII. Localization of antigenic sites responsible for immunochemical heterogeneity of kappa chains.

Authors:  C L McLaughlin; A Solomon
Journal:  J Biol Chem       Date:  1972-08-25       Impact factor: 5.157

3.  Bence-Jones proteins and light chains of immunoglobulins. I. Formation and characterization of amino-terminal (variant) and carboxyl-terminal (constant) halves.

Authors:  A Solomon; C L McLaughlin
Journal:  J Biol Chem       Date:  1969-06-25       Impact factor: 5.157

4.  Structural identity of Bence Jones and amyloid fibril proteins in a patient with plasma cell dyscrasia and amyloidosis.

Authors:  W D Terry; D L Page; S Kimura; T Isobe; E F Osserman; G G Glenner
Journal:  J Clin Invest       Date:  1973-05       Impact factor: 14.808

5.  Amyloid fibril protein related to immunoglobulin lambda-chains.

Authors:  M Skinner; M D Benson; A S Cohen
Journal:  J Immunol       Date:  1975-04       Impact factor: 5.422

6.  Subgroup-specific antigenic marker on immunoglobulin lambda chains: identification of three subtypes of the variable region.

Authors:  F W Tischendorf; M M Tischendorf; E F Osserman
Journal:  J Immunol       Date:  1970-10       Impact factor: 5.422

7.  N-terminal amino acid sequence of amyloid fibril protein AR, prototype of a new lambda-variable subgroup, V lambda V.

Authors:  K Sletten; G Husby; J B Natvig
Journal:  Scand J Immunol       Date:  1974       Impact factor: 3.487

Review 8.  Bence-Jones proteins and light chains of immunoglobulins (first of two parts).

Authors:  A Solomon
Journal:  N Engl J Med       Date:  1976-01-01       Impact factor: 91.245

9.  The purification of amyloid fibril proteins.

Authors:  G G Glenner; M Harada; C Isersky
Journal:  Prep Biochem       Date:  1972

10.  The characterization of soluble amyloid prepared in water.

Authors:  M Pras; M Schubert; D Zucker-Franklin; A Rimon; E C Franklin
Journal:  J Clin Invest       Date:  1968-04       Impact factor: 14.808

View more
  38 in total

1.  Structural relationship of kappa-type light chains with AL amyloidosis: multiple deletions found in a VkappaIV protein.

Authors:  M A Alim; S Yamaki; M S Hossain; K Takeda; M Kozima; T Izumi; I Takashi; T Shinoda
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

2.  Analysis of somatic hypermutation and antigenic selection in the clonal B cell in immunoglobulin light chain amyloidosis (AL).

Authors:  Roshini S Abraham; Susan M Geyer; Marina Ramírez-Alvarado; Tammy L Price-Troska; Morie A Gertz; Rafael Fonseca
Journal:  J Clin Immunol       Date:  2004-07       Impact factor: 8.317

3.  Aberrant immunoglobulin synthesis in light chain amyloidosis. Free light chain and light chain fragment production by human bone marrow cells in short-term tissue culture.

Authors:  J Buxbaum
Journal:  J Clin Invest       Date:  1986-09       Impact factor: 14.808

4.  Primary structure of a monoclonal kappa chain in myeloma with light chain deposition disease.

Authors:  A A Khamlichi; P Aucouturier; C Silvain; M Bauwens; G Touchard; J L Preud'homme; F Nau; M Cogné
Journal:  Clin Exp Immunol       Date:  1992-01       Impact factor: 4.330

5.  Structure of a monoclonal kappa chain of the V kappa IV subgroup in the kidney and plasma cells in light chain deposition disease.

Authors:  M Cogné; J L Preud'homme; M Bauwens; G Touchard; P Aucouturier
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

6.  Immunoelectrophoretic investigations in 55 patients with systemic amyloidosis.

Authors:  D Vital Durand; J L Touraine; R Levrat; P Zech; J Traeger; E Lejeune; R Creyssel
Journal:  Blut       Date:  1984-08

7.  AL-Base: a visual platform analysis tool for the study of amyloidogenic immunoglobulin light chain sequences.

Authors:  Kip Bodi; Tatiana Prokaeva; Brian Spencer; Maurya Eberhard; Lawreen H Connors; David C Seldin
Journal:  Amyloid       Date:  2009-03       Impact factor: 7.141

8.  Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2.

Authors:  Bonnie K Arendt; Marina Ramirez-Alvarado; Laura A Sikkink; Jonathan J Keats; Gregory J Ahmann; Angela Dispenzieri; Rafael Fonseca; Rhett P Ketterling; Ryan A Knudson; Erin M Mulvihill; Renee C Tschumper; Xiaosheng Wu; Steven R Zeldenrust; Diane F Jelinek
Journal:  Blood       Date:  2008-06-20       Impact factor: 22.113

9.  Induction in mice of human light-chain-associated amyloidosis.

Authors:  A Solomon; D T Weiss; M B Pepys
Journal:  Am J Pathol       Date:  1992-03       Impact factor: 4.307

Review 10.  Deposition-associated diseases related with a monoclonal compound.

Authors:  M J Molina-Garrido; C Guillén-Ponce; A Mora; M Guirado-Risueño; M A Molina; M J Molina; A Carrato
Journal:  Clin Transl Oncol       Date:  2007-12       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.